drugset / Trial / NCT02478645
Dose-ranging Study of Ramosetron for the Prevention of Nausea and Vomiting After Gynecologic Laparoscopic Surgery
RandomizedParallel-groupTriple-blindOther
Summary
Many patients receiving opioid based analgesia after gynecologic laparoscopic surgery experience postoperative nausea and vomiting (PONV) despite prophylaxis and treatment with HT3 receptor antagonists. Although a high dose of ramosetron can cause adverse effects such as headache or dizziness, the minimal effective dose of ramosetron in a high-risk patients is unknown. The aim of this study is to determine the effective dose of ramosetron for prophylaxis of PONV in a high-risk patients receiving intravenous opioid-based patient-controlled analgesia after gynecological laparoscopic surgery.
Timeline
- Start
- 2015-06-19
- Primary completion
- 2016-02-06
- Completion
- 2016-02-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ramosetron | Small molecule | 0.3 mg | — |
| Subject | Ramosetron | Small molecule | 0.45 mg | — |
| Subject | Ramosetron | Small molecule | 0.6 mg | — |
Indications
No indication recorded.